SB747651A-PEG3-VH-032

Target: SB747651A-PEG3-VH-032 is designed to recruit MSK1 kinase to VHL.

Binding site: Its SB747651A warhead engages the MSK1 ATP-binding catalytic pocket.

Mechanism of action: SB747651A-PEG3-VH-032 is a VHL-recruiting MSK1 PROTAC scaffold that combines the MSK1 inhibitor SB-747651A with the VHL ligand VH-032 through a PEG3 linker. This design explores whether a longer flexible linker can support a productive MSK1–PROTAC–VHL ternary complex and promote ubiquitin-proteasome-dependent kinase degradation. In research use, it enables comparison with PEG1 and CRBN-recruiting analogs to assess how linker length and E3 ligase selection influence target ubiquitination, degradation efficiency, selectivity, and cellular pathway modulation.

• PROTAC-Driven Cancer Research: This compound, SB747651A-PEG3-VH-032, is instrumental in investigating the selective degradation of oncogenic proteins. By facilitating the removal of specific cancer-related proteins, researchers can explore new therapeutic strategies and gain insights into tumorigenesis mechanisms.

• Targeted Protein Degradation in Neurodegenerative Studies: SB747651A-PEG3-VH-032 aids in the study of neurodegenerative diseases by enabling the targeted degradation of proteins implicated in neuronal dysfunction. This allows researchers to dissect disease pathways and evaluate the potential for therapeutic intervention.

• PROTAC-Based Drug Discovery: Utilizing SB747651A-PEG3-VH-032 in drug discovery pipelines enhances the identification of novel targets for small-molecule drug development. By degrading specific proteins, it provides a robust platform for validating target engagement and efficacy in preclinical models.

• Mechanistic Studies of Protein Degradation: The use of SB747651A-PEG3-VH-032 facilitates detailed mechanistic studies of the ubiquitin-proteasome system. Researchers can employ this PROTAC to elucidate pathways involved in protein turnover and stability, advancing our understanding of cellular homeostasis.